2BBBullish & Bearish
Amarin Corporation PLC (AMRN) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 22 out of 100.
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid. In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza.
Amarin Corporation PLC’s current 2BB score is 22 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 0 | Very Low |
| Momentum | 50 | Stable |
| Financial strength | 24 | Weak |
| Quality | 20 | Weak |
| Risk | 37 | Low |
| Headquarters | Dublin, Leinster, Ireland |
| Founded | Mar 1, 1989 |
| Employees | 80 |
| 52-week range | $13.12 – $20.90 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-23 | — | -0.0102 | — | $44.43M |
| 2026-10-27 | — | -0.0204 | — | $42.25M |
| 2026-07-29 | — | -0.0102 | — | $45.44M |
| 2026-04-29 | -0.09 | 0.0867 | $45.13M | $44.65M |